Moleculin Announces Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting
Rhea-AI Summary
Moleculin (Nasdaq: MBRX) announced an abstract on its lead candidate annamycin was accepted for a poster at the 2026 ASCO Annual Meeting, held May 29–June 2, 2026 in Chicago.
The poster, “Cardiac safety of L-annamycin at high cumulative anthracycline exposure: Pooled analysis,” will be presented May 30, 2026, 1:30–4:30 PM CDT at Poster Board #8 in the Symptom Science and Palliative Care session.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – MBRX
On the day this news was published, MBRX declined 1.17%, reflecting a mild negative market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $153K from the company's valuation, bringing the market cap to $12.92M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
MBRX gained 5.79% while peers were mixed: LPTX up 238.84%, SNGX up 6.98%, but KZIA, INTS, and MBIO down modestly. Momentum scanner only flagged SNSE up 10.70%, suggesting today’s move is stock-specific rather than a broad biotech rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 07 | Safety profile update | Positive | +3.9% | CEO Corner segment highlighted Annamycin’s non-cardiotoxic safety profile. |
| Mar 23 | Trial enrollment milestone | Positive | +1.9% | Hit 45-subject enrollment in MIRACLE trial, triggering interim data countdown. |
| Mar 19 | Earnings and trial update | Positive | -1.0% | Reported 2025 results and reiterated MIRACLE interim data timing and CRc rate. |
| Mar 17 | Conference appearance | Neutral | +5.4% | Announced participation in the 38th Annual ROTH investor conference. |
| Mar 11 | MIRACLE trial overview | Positive | +3.0% | CEO Corner detailed MIRACLE study design and upcoming 45-patient interim analysis. |
Recent Moleculin news, especially MIRACLE trial and Annamycin safety updates, has often coincided with modestly positive next-day price reactions, with one earnings-related divergence.
Over the past six weeks, Moleculin has repeatedly emphasized Annamycin’s efficacy and cardiac safety profile. On March 11 and March 23, 2026, CEO Corner and 8-K updates highlighted progress in the pivotal MIRACLE trial and its 45-patient interim unblinding. Subsequent news on enrollment milestones and safety messaging, including the April 7 CEO segment on non-cardiotoxicity, generally saw positive price reactions. Today’s ASCO abstract on cardiac safety extends this theme of differentiating Annamycin on tolerability while the program advances toward key mid-2026 data.
Regulatory & Risk Context
An effective S-3 shelf filed on March 27, 2026 registers 6,367,956 warrant-linked shares for resale. Full cash exercise of these warrants at $2.3976 per share would yield gross proceeds of $15.3 million to the company, while enabling selling stockholders to resell registered shares under the shelf.
Market Pulse Summary
This announcement highlights acceptance of an ASCO 2026 poster describing a pooled analysis of annamycin’s cardiac safety at high cumulative anthracycline exposure. It reinforces prior disclosures that emphasize a potentially differentiated, non-cardiotoxic profile as the MIRACLE trial advances toward interim data in mid-2026. Investors may watch upcoming ASCO details, the planned 45-patient interim readout, and ongoing warrant-related resale capacity under the effective S-3 when assessing future risk-reward.
Key Terms
anthracycline medical
cardiotoxicity medical
pooled analysis technical
AI-generated analysis. Not financial advice.
HOUSTON, April 21, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that an abstract highlighting data on its lead drug candidate, annamycin, has been accepted for poster presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 – June 2, 2026, in Chicago, Illinois.
The abstract, titled “Cardiac safety of L-annamycin at high cumulative anthracycline exposure: Pooled analysis,” will be presented in a poster session focused on Symptom Science and Palliative Care.
Presentation Details:
- Session Type: Poster Session - Symptom Science and Palliative Care
- Presentation Date and Time: May 30, 2026, 1:30 PM – 4:30 PM CDT
- Location: Poster Board #8
The abstract presents a pooled analysis evaluating the cardiac safety profile of annamycin in patients with high cumulative exposure to anthracyclines, an important consideration given the known risk of cardiotoxicity associated with this class of chemotherapeutic agents.
“We are pleased to have this abstract accepted for presentation at ASCO, one of the most prestigious oncology conferences globally,” said Walter Klemp, Chairman and CEO of Moleculin. “These data further support the potential of annamycin as a differentiated anthracycline with a favorable cardiac safety profile, even at higher cumulative exposure levels. We look forward to sharing these findings with the oncology community.”
The ASCO Annual Meeting is one of the largest and most influential gatherings of oncology professionals worldwide, featuring cutting-edge research and advances in cancer treatment. For more information, please visit asco.org.
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and viruses. The Company’s lead program, Annamycin (also known as naxtarubicin), is a next-generation highly efficacious and well tolerated anthracycline designed to avoid multidrug resistance mechanisms and to lack the cardiotoxicity common with currently prescribed anthracyclines. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.
The Company has begun the MIRACLE (Moleculin R/R AML AnnAraC Clinical Evaluation) Trial (MB-108), a pivotal, adaptive design Phase 3 trial evaluating Annamycin in combination with cytarabine, together referred to as AnnAraC (the combination of Annamycin and cytarabine, also referred to as “Ara-C”) for the treatment of relapsed or refractory acute myeloid leukemia. Following a successful Phase 1B/2 study (MB-106), with input from the FDA, the Company believes it has substantially de-risked the development pathway towards a potential approval for Annamycin for the treatment of AML. This study remains subject to appropriate future filings with potential additional feedback from the FDA and their foreign equivalents.
Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers. Moleculin also has in its pipeline a portfolio of antimetabolites, including WP1122 for the potential treatment of pathogenic viruses, as well as certain cancer indications.
For more information about the Company, please visit www.moleculin.com and connect on X, LinkedIn and Facebook.
Forward-Looking Statements
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the expected timing and results of the 45-subject interim data unblinding in the MIRACLE trial, the anticipated clinical milestones set forth above, and the potential efficacy and safety of Annamycin and AnnAraC in R/R AML and other indications. Moleculin will require significant additional financing, for which the Company has no commitments, in order to conduct its clinical trials as described in this press release, and the milestones described in this press release assume the Company’s ability to secure such financing on a timely basis. Although Moleculin believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. The Company relies on the reports of its expert with regard to the absence of cardiotoxicity. The dataset referenced in this press release is subject to the review of the data from future subjects in its current and future clinical trials and long-term follow-up with subjects in its current trials. Moleculin has attempted to identify forward-looking statements by terminology including ‘believes,’ ‘estimates,’ ‘anticipates,’ ‘expects,’ ‘plans,’ ‘projects,’ ‘intends,’ ‘potential,’ ‘may,’ ‘could,’ ‘might,’ ‘will,’ ‘should,’ ‘approximately’ or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. “Risk Factors” in our most recently filed Form 10-K filed with the Securities and Exchange Commission (SEC) and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
MBRX@jtcir.com
